Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE)

Trial Profile

BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azathioprine (Primary) ; Mycophenolate mofetil (Primary) ; Antirheumatics; Belimumab; Cyclophosphamide; Immunomodulators; Immunosuppressants; Rituximab
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms BILAG-BR
  • Most Recent Events

    • 03 Jun 2023 Results of all-cause mortality rate (MR) and the incidence of cancer in SLE patients receiving biologic and standard of care therapies, presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Results assessing differential response of patients with moderate-severe SLE in the UK by ethnic background, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 04 Jun 2022 Results assessing COVID-19 infections, hospitalisation and recovery in a real-world cohort of patients with moderate to severe SLE presented at the 23rd Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top